Tesamorelin (10mg)

Description

What is Tesamorelin?

Tesamorelin is a stabilized synthetic analog of growth hormone–releasing hormone (GHRH) consisting of 44 amino acids with an N-terminal trans-3-hexenoic acid modification that extends its half-life. It is approved by the FDA (brand name Egrifta®) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy and has been studied in multiple human clinical trials for visceral adipose tissue reduction and cognitive function in aging adults.

Mechanism of Action

• Selective agonism of pituitary GHRH receptors
• Stimulation of pulsatile endogenous growth hormone (GH) release
• Downstream increases in circulating IGF-1

Compound Properties

• Molecular formula: C221H366N72O67S
• Molecular weight: 5,135.9 g/mol
• CAS number: 218949-48-5
• Form: Lyophilized powder
• Unit size: 10 mg/vial
• Source reference: PubChem CID 16137828

Research-Reference Dosing

Human trial dosing from published peer-reviewed studies. Provided for research reference only.

• HIV-lipodystrophy trials: 2 mg subcutaneous once daily (Falutz et al., NEJM 2007; Stanley et al., JAMA 2014)
• Cognitive aging study: 1 mg subcutaneous daily for 20 weeks (Baker et al., Arch Neurol 2012)
• NAFLD reduction trial: 2 mg subcutaneous once daily for 12 months (Stanley et al., Lancet HIV 2019)

Research Findings (Published Human Data)

• ~15–18% reduction in visceral adipose tissue over 26 weeks in HIV-lipodystrophy trials
• Significant reduction in liver fat fraction in NAFLD studies
• Improvements in executive function and verbal memory in healthy older adults and those with mild cognitive impairment
• Increased IGF-1 within physiologic range

Known Side Effects Reported in Trials

• Common: injection-site redness/itching, arthralgia, myalgia, peripheral edema
• Less common: glucose intolerance/hyperglycemia, carpal tunnel symptoms, headache
• Serious/rare: hypersensitivity reactions; caution with active malignancy or pituitary tumors

Storage & Handling

Store lyophilized vial at 2–8°C, protected from light. After reconstitution, refrigerate and use promptly per handling guidelines in the relevant literature.

Certificate of Analysis

A product-specific Certificate of Analysis (CoA) is available upon request for every lot.